Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 6 Toxicity of the clinical trials with doxorubicin

From: Nanomedicine review: clinical developments in liposomal applications

ReferencesDiseaseLFToxicity
Grade 3–5 (%)
HematologicalNon-hematological
NTLAFNaDVS/MHFSR
Banerjee et al. (2018)ROCPLD4   6 266  
Lee et al. (2017)ROCPLD73 4       
Monk et al. (2017)aROCPLD    74.1  33.3  4.1
Marth et al. (2017)ROCPLD15  455566122
Lindemann et al. (2017)ROCPLD 2 2 7 7   
Herzog et al. (2016)ROCPLD13  13       
Runnebaum et al. (2018)ROCPLD + trebananib181015  5 5   
Lee et al. (2017)ROCPLD + carboplatin2613 8       
Sehouli et al. (2016)ROCPLD + carboplatin271517102     2
Nagao et al. (2016)ROCPLD + paclitaxel + carboplatin833383100 17  5017 
Landrum et al. (2016)ROCPLD + carboplatin + bevacizumab + veliparib304030        
Kim et al. (2015)ROCPLD + carboplatin + farletuzumab40  1367332020 3333
Monk et al. (2017)aROCPLD + motolimod    87.8  50.3  10.9
Marth et al. (2017)ROCPLD + trebananib8  476367202
Shoji et al. (2017)ROCPLD + irinotecan553321033310   
Thaker et al. (2017)ROCPLD + GEN71 5728    28  
Herzog et al. (2016)ROCPLD + vintafolide17 5     5  
Jehn et al. (2016)MBCCaelix®   4     12 
Harbeck et al. (2016)MBCPLD31414   639 
Chang et al. (2018)MBCPLD + cyclophosphamide42 475 10 51  
Tampaki et al. (2018)BCPLD + cyclophosphamide + bevacizumab + paclitaxel241.6   6.5 1.69.7  
Basho et al. (2016)TNBCPLD + bevacizumab + temsirolimus84  4   813 
PLD + bevacizumab + everolimus2211 2222   11  
Rocca et al. (2017)BCPLD + lapatinib      11 1111 
Coltelli et al. (2017)BCMyocet® + cyclophosphamide + PTX25    646   
Cohen et al. (2018)MMPLD + pomalidomide + dexamethasone51438319      
Orlowski et al. (2016)RMMPLD + bortezomib           
Becker et al. (2016)MMPLD + bortezomib + cyclophosphamide + dexamethasone10  5  5 510 
Voorhees et al. (2017)RMMPLD + bortezomib + vorinostat3747  169199 9 
Luminari et al. (2017)DLBCLMyocet® + cyclophosphamide + vincristine + prednisone648 46 2     
Fridrik et al. (2016)DLBCLMyocet® + cyclophosphamide + vincristine + prednisone + rituximab50 5085      29
  1. In the blanks, this type of toxicity is not reported
  2. LF liposomal formulation, N neutropenia, T thrombocytopenia, L leukopenia, A anemia, F fatigue, Na nauseas, D diarrhea, V vomiting, S/M stomatitis/mucositis, HFS hand–foot syndrome, R rash, PLD PEGylated liposomal doxorubicin, GEN an IL-12 plasmid formulated with PEG–PEI–cholesterol lipopolymer, ROC recurrent ovarian cancer, MBC metastatic breast cancer, BC breast cancer, TNBC triple-negative breast cancer, RMM relapse or refractory multiple myeloma, MM multiple myeloma, DLBCL relapse or refractory multiple myeloma
  3. aAny serious adverse event = 3.4 and 8.2% in PLD and PLD + motolimod injections, respectively